

RECLAIM-LN Study (FT819-201)

Do you or someone you love have lupus nephritis (LN)?



The **RECLAIM-LN Study (FT819-201)** is now enrolling people with moderate-to-severe lupus nephritis (LN) to join the study. This study will test a new investigational treatment for LN.

Ask your doctor for more information about this new investigational product and study; and if participating would be appropriate for you.



Lupus nephritis research



Lupus nephritis (LN) is a condition that can happen with systemic lupus erythematosus (SLE), also called Lupus.

Lupus is an autoimmune disease. This means the body's immune or "defense" system which normally protects you from illness, mistakenly attacks parts of the body. When lupus affects the kidneys, it is called lupus nephritis. Without a treatment, the kidneys can become damaged and stop working.


Current medicines can help control LN, but they don't work well for everyone. Some people continue to have kidney damage even with treatment. That is why researches are studying new treatments that might help control the disease.

RECLAIM-LN is a clinical study evaluating a potential new treatment option that may help people with LN who have not responded adequately to existing treatment options¹.

Evaluating a potential new treatment option

This study is evaluating a potential new treatment option called FT819. FT819 is a type of CAR T-cell therapy².

- T cells are white blood cells that protect you from foreign invaders, like viruses, inside your body.
- This investigational therapy (FT819) contains specially prepared T cells. These special T cells are designed to find and remove certain immune cells that may cause damage to the kidneys in people with LN.



Other CAR T-cell therapies have been approved for the treatment of several blood cancers, including leukemia, lymphoma, and multiple myeloma.

CAR T-cell therapies may help destroy the harmful white blood cells responsible for causing LN, potentially leading to significant improvement or remission of disease.

1. Sandhu, V. *et al.* Annals of the Rheumatic Diseases, Volume 84, Supplement 1 (2025).
2. FT819 is an investigational product that has not been approved or authorized for commercial use by any regulatory authority.



About the **RECLAIM-LN** Study

The **RECLAIM-LN (FT819-201)** Study is testing a new investigational product called FT819³. Researchers want to learn how safe it is and whether it can help people aged 12 to 70 with moderate-to-severe LN who have not improved enough with current treatments.

What to Expect:

Screening: Before you can join the study, the study doctor will ask you some questions and do some tests to see if the study is a good fit for you.

Treatment Period (~4 weeks): Before you receive the product, you will be given medicines to prepare your immune system. You will then receive the study drug through a single intravenous (IV) infusion. After the infusion, the study team will monitor you for 7 days and you will be required to stay in the hospital for 3 days.

Follow-Up (up to 2 years): After you receive the study drug, you will return for regular study visits for up to 2 years. During these visits, you may have physical exams, blood and urine tests, and be asked to answer questions about your health and how you are feeling.

Long-Term Follow-Up (up to 15 years): After the 2-year follow-up is complete, the study team will continue to check on your health from time to time for up to 13 more years, a total of 15 years from when you receive FT819. These check-ins may be done during a clinic visit, by phone, or by email. No extra medical tests or laboratory tests will be required beyond the care you would normally receive.



Qualifying for the study

Am I Eligible?

Before joining the **RECLAIM-LN** Study, you will go through a screening period to check if you qualify. This involves some basic tests and assessments. To be eligible, you must:

- Be between age 12 – 70 years old.
- Have a diagnosis of SLE with kidney involvement (LN).
- Have moderate-to-severe disease that has not responded well to standard treatments.
- Additional eligibility criteria will be assessed by your care team.

What Does Participation Cost?

Nothing. Study-related visits, lab tests, and procedures are provided at no cost. You may also be reimbursed for travel, transportation, and time depending on your location. Ask the study team for details.

Interested? Speak with your doctor to find out if the **RECLAIM-LN** Study may be right for you.

3. FT819 is an investigational product that has not been approved or authorized for commercial use by any regulatory authority



This image shows a full page of blank, lined paper. It features approximately 20 evenly spaced horizontal grey lines across its entire width, providing a template for writing or drawing. The margins are consistent on all sides.

FT819 is an investigational product that has not been approved or authorized for commercial use by any regulatory authority.

Talk with your doctor to see if joining this study could be the right step for you. Together you can decide what's best for your health and future

